决定异体 CAR T 细胞排斥与扩增的细胞和分子机制

Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

整合跨膜 CD28 结构域后学术性 CAR-T ARI0002h 对正常和低表达 BCMA 骨髓瘤细胞增强的抗肿瘤活性

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane

将 CD28-TMD 整合到 ARI0002h CAR 中可增强肿瘤控制，即使在靶抗原下调的复发模型中也是如此，从而提供更好的长期疾病管理。该修饰增强了对 BCMA 表达正常和降低的 MM 肿瘤细胞系的效力，表现出更优的代谢耐力和体内活性。

CXCR4 修饰通过改善 B 细胞恶性肿瘤的肿瘤追踪与骨髓归巢增强 CAR-T 疗效

CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies.

超越免疫检查点阻断：T 细胞衔接器与抗体药物偶联物在癌症与自身免疫性疾病中的应用

Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease.

CAR-T 细胞治疗前基于苯达莫司汀的淋巴细胞清除：一项系统综述

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

事实与希望：CAR-T 细胞治疗与非霍奇金淋巴瘤免疫构成

Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.

使用溶瘤病毒将 T 细胞衔接器重定向以靶向实体瘤的通用即用型联合免疫疗法

Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors.

我们的研究结果表明，OV 与 TCEs 的联合提供了一种有前景的策略，可驱动针对实体瘤的抗肿瘤免疫应答。该方法代表了一种新颖且通用的平台，目前正处于将 TCE 疗法与溶瘤病毒疗法联合的 1 期临床试验中，克服了抗原异质性和免疫屏障，从而实现实体瘤的有效治疗。

从 CAR-T 到 CAAR-T：通过独特型导向细胞治疗重新定义 B 细胞恶性肿瘤的靶向策略

From CAR-T to CAAR-T: redefining targeting strategies in B-cell malignancies through idiotype-directed cellular therapy.

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.